3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
4
Phase 2
3
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Lung Neoplasms
5
Carcinoma, Non-Small-Cell Lung
5
Squamous Cell Carcinoma of Head and Neck
4
Sezary Syndrome
3
Mycosis Fungoides
3
Carcinoma, Renal Cell
3
Urinary Bladder Neoplasms
2
Triple Negative Breast Neoplasms
2
Prostatic Neoplasms
2
Melanoma
2
Lymphoma, T-Cell, Cutaneous
2
Fallopian Tube Neoplasms
2
Carcinoma, Hepatocellular
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urogenital Neoplasms
1
Rectal Neoplasms
1
Platinum-Refractory Fallopian Tube Carcinoma
1
Ovarian Neoplasms
1
Oropharyngeal Neoplasms
1
Oligodendroglioma
1
Neoplasm Metastasis
1
Lymphoma, T-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
Extensive Stage Lung Small Cell Carcinoma
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Interventions
pembrolizumab
43
Nivolumab
24
Gemcitabine
23
Cyclophosphamide
22
Paclitaxel
17
Capecitabine
16
fludarabine
15
Ipilimumab
14
aldesleukin
11
Docetaxel
11
130-nm albumin-bound paclitaxel
11
Trastuzumab
10
Cetuximab
10
Bevacizumab
10
Albumin-Bound Paclitaxel
9
fludarabine phosphate
8
Specimen Handling
8
Interleukin-2
8
Fluorouracil
8
Cisplatin
8
Biopsy
8
Radiosurgery
7
Oxaliplatin
7
Irinotecan
7
durvalumab
6
avelumab
6
Temozolomide
6
Pemetrexed
6
Leucovorin
6
Carboplatin
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Neoplasm Metastasis
×
Immunoglobulin G
×
Clear all
NCT05269381
2026-03-12
PNeoVCA
Mayo Clinic
Phase 1/2
Recruiting
132 enrolled